INTRODUCTION AND HYPOTHESIS: The purpose of this study was to assess cost utility of duloxetine versus tension-free vaginal tape (TVT) as a second-line treatment for urinary stress incontinence. METHODS: A Markov model was used to compare the cost utility based on a 2-year follow-up period. Quality-adjusted life year (QALY) estimation was performed by assuming a disutility rate of 0.05. RESULTS: Under base-case assumptions, although duloxetine was a cheaper option, TVT gave a considerably higher QALY gain. When a longer follow-up period was considered, TVT had an incremental cost-effectiveness ratio (ICER) of pound 7,710 ($12,651) at 10 years. If the QALY gain from cure was 0.09, then the ICER for duloxetine and TVT would both fall within the indicative National Institute for Health and Clinical Excellence willingness to pay threshold at 2 years, but TVT would be the cost-effective option having extended dominance over duloxetine. CONCLUSIONS: This model suggests that TVT is a cost-effective treatment for stress incontinence.
INTRODUCTION AND HYPOTHESIS: The purpose of this study was to assess cost utility of duloxetine versus tension-free vaginal tape (TVT) as a second-line treatment for urinary stress incontinence. METHODS: A Markov model was used to compare the cost utility based on a 2-year follow-up period. Quality-adjusted life year (QALY) estimation was performed by assuming a disutility rate of 0.05. RESULTS: Under base-case assumptions, although duloxetine was a cheaper option, TVT gave a considerably higher QALY gain. When a longer follow-up period was considered, TVT had an incremental cost-effectiveness ratio (ICER) of pound 7,710 ($12,651) at 10 years. If the QALY gain from cure was 0.09, then the ICER for duloxetine and TVT would both fall within the indicative National Institute for Health and Clinical Excellence willingness to pay threshold at 2 years, but TVT would be the cost-effective option having extended dominance over duloxetine. CONCLUSIONS: This model suggests that TVT is a cost-effective treatment for stress incontinence.
Authors: Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein Journal: Neurourol Urodyn Date: 2002 Impact factor: 2.696
Authors: Daniëlle E M Brunenberg; Manuela A Joore; Christiaan P W M Veraart; Bary C M Berghmans; C Huub van der Vaart; Johan L Severens Journal: Clin Ther Date: 2006-04 Impact factor: 3.393
Authors: Smriti Iyengar; Amy A Webster; Susan K Hemrick-Luecke; Jimmy Yu Xu; Rosa Maria A Simmons Journal: J Pharmacol Exp Ther Date: 2004-07-13 Impact factor: 4.030
Authors: Aura Pyykönen; Pasi Aronen; Pirjo Räsänen; Risto P Roine; Jari Sjöberg; Anna-Maija Tapper Journal: Int Urogynecol J Date: 2013-09-06 Impact factor: 2.894
Authors: Mohamed Abdel-Fattah; Graeme MacLennan; Mary Kilonzo; R Phil Assassa; Kirsty McCormick; Tracey Davidson; Alison McDonald; James N'Dow; Judith Wardle; John Norrie Journal: BMJ Open Date: 2017-08-11 Impact factor: 2.692
Authors: Mehdi Javanbakht; Eoin Moloney; Miriam Brazzelli; Sheila Wallace; Muhammad Imran Omar; Ash Monga; Lucky Saraswat; Phil Mackie; Mari Imamura; Jemma Hudson; Michal Shimonovich; Graeme MacLennan; Luke Vale; Dawn Craig Journal: Syst Rev Date: 2020-04-20